147 related articles for article (PubMed ID: 35190214)
1. Myasthenia gravis induced by pembrolizumab in a patient with metastatic Merkel cell carcinoma.
Pottier C; El Habnouni C; Kervarrec T; Beltran S; Samimi M
Ann Dermatol Venereol; 2022 Jun; 149(2):142-145. PubMed ID: 35190214
[No Abstract] [Full Text] [Related]
2. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
3. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-associated ocular myasthenia gravis.
Liu Q; Ayyappan S; Broad A; Narita A
Clin Exp Ophthalmol; 2019 Aug; 47(6):796-798. PubMed ID: 30859689
[No Abstract] [Full Text] [Related]
5. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
6. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.
Lau KH; Kumar A; Yang IH; Nowak RJ
Muscle Nerve; 2016 Jun; 54(1):157-61. PubMed ID: 27065302
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab-induced myasthenia gravis: A fatal case report.
March KL; Samarin MJ; Sodhi A; Owens RE
J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928
[TBL] [Abstract][Full Text] [Related]
8. Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
Zaremba A; Chorti E; Jockenhöfer F; Bolz S; Sirin S; Glas M; Becker JC; Ugurel S; Roesch A; Schadendorf D; Livingstone E; Hagenacker T; Zimmer L
J Immunother Cancer; 2019 May; 7(1):141. PubMed ID: 31142383
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy.
Marchand A; Kervarrec T; Bhatia S; Samimi M
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1093-1106. PubMed ID: 33044876
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma.
Haug V; Behle V; Benoit S; Kneitz H; Schilling B; Goebeler M; Gesierich A
Br J Dermatol; 2018 Oct; 179(4):993-994. PubMed ID: 29758087
[No Abstract] [Full Text] [Related]
11. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab-induced Myasthenia Gravis Relapse after Immunosuppressive Therapy.
Oshima Y; Fujii S; Horiuchi K
Intern Med; 2022 Nov; 61(21):3281-3285. PubMed ID: 35400705
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report.
Kiaei B; Chaudhry M; Banerjee S; Brewer J; Chen Y; Khasiyev F; Guzman MA; Hayat G
BMC Neurol; 2024 Jun; 24(1):184. PubMed ID: 38824498
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab as first line treatment of Merkel cell carcinoma patients - a case series of patients with various co-morbidities.
Bystrup Boyles T; Schødt M; Hendel HW; Krarup-Hansen A; Junker N
Acta Oncol; 2020 Jul; 59(7):793-796. PubMed ID: 32285728
[No Abstract] [Full Text] [Related]
15. [A case of myasthenia gravis and myositis induced by pembrolizumab].
Noda T; Kageyama H; Miura M; Tamura T; Ito H
Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
[TBL] [Abstract][Full Text] [Related]
16. Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis.
Moradi LA; Clark CA; Schneider CS; Deshane AS; Dobelbower MC
Front Immunol; 2021; 12():788499. PubMed ID: 34956219
[TBL] [Abstract][Full Text] [Related]
17. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma.
Shirai T; Sano T; Kamijo F; Saito N; Miyake T; Kodaira M; Katoh N; Nishie K; Okuyama R; Uhara H
Jpn J Clin Oncol; 2016 Jan; 46(1):86-8. PubMed ID: 26491202
[TBL] [Abstract][Full Text] [Related]
18. [Re-Administration of Pembrolizumab for Urothelial Carcinoma after immune-Related Myasthenia Gravis : A Case Report].
Kurokawa M; Shimizu K; Kitabayashi R; Ogawa K; Okada Y; Kubo K; Yamaguchi D; Okubo K
Hinyokika Kiyo; 2022 Sep; 68(9):295-300. PubMed ID: 36199208
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report.
Tian CY; Ou YH; Chang SL; Lin CM
J Med Case Rep; 2021 Apr; 15(1):244. PubMed ID: 33926558
[TBL] [Abstract][Full Text] [Related]
20. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis.
Zhao S; Zhou Y; Sun W; Li Z; Wang C
Clin Exp Immunol; 2023 Mar; 211(2):85-92. PubMed ID: 36426591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]